Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye diseases
Biotech
Atsena downsizes to funnel money toward new capsid program
Atsena Therapeutics has cut staff to funnel more money toward an inherited retinal disease program that just began in August.
Max Bayer
Oct 5, 2023 1:47pm
Astellas to test out 4DMT's eye disease gene therapy vector
Jul 10, 2023 7:30pm
Boehringer taps RetinAI for AI boost to eye disease R&D
Apr 21, 2023 9:35am
Pixium Vision's bionic eye implant nets FDA breakthrough label
Apr 3, 2023 9:00am
AbbVie pays $70M to expand Capsida collab into eye disease
Feb 23, 2023 5:00am
Unity's ophthalmology asset improves vision in phase 2
Nov 1, 2022 11:10am
